

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM769204

SUBMISSION TYPE:	RESUBMISSION		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
RESUBMIT DOCUMENT ID:	900719730		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Oncology Analytics, Inc.		09/13/2022	Corporation: FLORIDA
RECEIVING PARTY DATA			
Name:	Oncology Analytics, Inc.		
Street Address:	7000 Central Parkway, Suite 1750		
City:	Atlanta		
State/Country:	GEORGIA		
Postal Code:	30328		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	5053670	ONCOLOGY ANALYTICS	
Registration Number:	6748916	ONCOHEALTH	
Registration Number:	6607230	ONEUM	
Registration Number:	5594378	MATIS	
CORRESPONDENCE DATA			
Fax Number:	9549774717		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	9549774711		
Email:	mrichter@RichterTrademarks.com		
Correspondent Name:	Miriam Richter		
Address Line 1:	2312 Wilton Drive, Suite 9		
Address Line 4:	Wilton Manors, FLORIDA 33305		
NAME OF SUBMITTER:	Miriam Richter		
SIGNATURE:	/Miriam Richter/		
DATE SIGNED:	11/21/2022		
Total Attachments: 2			
source=Assignment of Trademark and Related Rights 1 - signed#page1.tif			

ASSIGNMENT OF INTELLECTUAL PROPERTY

This Assignment of Intellectual Property (“Assignment”) is entered into by and between Oncology Analytics, Inc, a Florida foreign corporation located at 7000 Central Parkway, Suite 1750, Atlanta, Georgia, 30328 (hereinafter called “the Assignor”) and Oncology Analytics, Inc. a Delaware corporation, with an address of 7000 Central Parkway, Suite 1750, Atlanta, Georgia, 30328 (hereinafter called “the Assignee”) (collectively “the Parties”).

This Assignment shall be effective as of September 12, 2022 (“Effective Date”).

Recitals

- A. WHEREAS, for at least the past many years, Assignor has dedicated time, effort, and expense into developing a line of services and related goods under the Onco Health brand including, but not limited to obtaining United States Federal Trademark Registrations No. 5053670, 6748916, 6607230, and 5594378, in International Classes 9, and 44(the Intellectual Property).
- B. Assignee desires to acquire all of Assignor’s right, title, goodwill, and interest in the Intellectual Property.
- C. Assignor seeks to give, grant, sell, transfer, convey and assign (collectively “assign”) to Assignee all of its right, title, goodwill, and interest in the Intellectual Property.

Assignment

NOW, THEREFORE, for consideration, the sufficiency and receipt of which is hereby acknowledged, Assignor and Assignee agree to the following terms:

- A. Rights Assigned. Assignor does hereby assign unto Assignee all of Assignor’s right, title, goodwill, and interest in the Intellectual Property as stated above to be held, enjoyed, prosecuted, and maintained by Assignee, for its own use and enjoyment, and for the use and enjoyment of its successors and assigns, or other legal representatives, for the full life of the Intellectual Property as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been entered into by the parties. Assignee shall prepare and file with the United States Patent and Trademark Office a formal notice of trademark assignment.
- B. Warranty. Assignor hereby represents and warrants that Assignor has the full power, authority and right to assign the Intellectual Property as herein provided; that Assignor has not previously granted, conveyed, licensed, sold, transferred, or assigned to any other party any right, title, goodwill, or interest in or to the Intellectual Property, nor will Assignor hereafter do any of the foregoing.

- D. Assignment. This Assignment and all obligations and undertakings hereunder shall inure to the benefit of Assignor and Assignee and their respective employees, agents, successors, assigns, transferees, heirs and executors.
- E. (a) This Assignment may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument, and shall become effective when counterparts have been signed by each of the Parties and delivered to the other Parties; it being understood that all Parties need not sign the same counterparts.
- (b) The exchange of copies of this Assignment and of signature pages by facsimile transmission (whether directly from one facsimile device to another by means of a dial-up connection or whether mediated by the worldwide web), by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, or by combination of such means, shall constitute effective execution and delivery of this Assignment as to the Parties and may be used in lieu of the original Assignment for all purposes. Signatures of the Parties transmitted by facsimile shall be deemed to be their original signatures for all purposes.

For the Assignor:

Ashley Brevda
Corporate Counsel/Chief Compliance Officer

DocuSigned by:

57B95418B37A490

Signature

Executed this 13 day of September, 2022.

For the Assignee:

Ashley Brevda
Corporate Counsel/Chief Compliance Officer

DocuSigned by:

57B95418B37A490

Signature

Executed this 13 day of September, 2022.